Stocks analysis

Analysis for MTD

  • 📈 Growth — 12/30
  • 💰 Profitability — 18/20
  • 🏦 Financial Health — 10/20
  • 💵 Valuation — 12/20
  • ⚠️ Risk — 6/10
Overall Score: 56/100

Summary:


📈 Growth & Financial Trajectory

Eight quarters show revenue stability around $1.0B to $1.13B, starting at $1.045B (Q3 2024) and ending at $1.028B (Q2 2026); net income moved from $252M to $233M, with a trough in Q4 2024 and Q1 2025, then a late-2025 peak of about $286M. Gross margins remained solid around 59%-63%, supporting earnings despite revenue volatility. The trend suggests resilience with a modest expansion during peak quarters but a slight overall drift lower from start to end.

💰 Margins & Cash Flow

  • Gross margin consistently near 59%-63%; Operating margin ranged roughly 22%-32% across quarters, indicating healthy operating leverage during peaks.
  • Net cash from operating activities remained positive across periods (roughly $140M to $310M per quarter); investing cash flow was negative and financing activities often contributed to cash flow variation, leading to a modest overall cash flow.

🛡️ Balance Sheet & Liquidity

  • Current assets around $1.1B–$1.35B vs current liabilities around $1.0B–$1.2B; liquidity via a modest current ratio near ~1.1–1.2.
  • Equity frequently negative (deficits) with long-term debt near $2.0B; assets cover liabilities, but negative equity and leverage pose execution risk.

⚠️ Key Drivers & Risks

  • Drivers: Durable demand for precision measurement instruments in manufacturing and life sciences; strong brand and product mix supporting margins.
  • Risks: Cyclical capital expenditure and macro sensitivity; elevated debt and recurring negative equity create valuation and liquidity risk.